Aerie Pharmaceuticals Reports Strong Progress in Retinal Program

Aerie Pharmaceuticals - OIS@ASCRS (2018)Подробнее

Aerie Pharmaceuticals - Public Company Showcase at Ophthalmology Innovation Summit @ ASRS 2019Подробнее

Aerie Pharmaceuticals: Moving Beyond Glaucoma (OIS@ASRS 2016)Подробнее

Clinical Progress of Aerie Pharmaceuticals’ Rhopressa and RoclatanПодробнее

David A. Hollander, MD, MBA - Aerie PharmaceuticalsПодробнее

Aerie PharmaceuticalsПодробнее

Aerie Pharmaceuticals - Innovation Showcase at Ophthalmology Innovation Summit @ ASCRS 2019Подробнее

Aerie Pharmaceuticals, Inc.Подробнее

Aerie COO Mitro Provides Staffing, Pipeline UpdateПодробнее

Aerie Looks for Rhopressa NDA in Q3Подробнее

How does Tom Mitro, President of Aerie Pharmaceuticals feel about reimbursement for doctors?Подробнее

Year in Review: Top Medications of the Year | Medication Highlights CompilationПодробнее

Mitro gives an update on AerieПодробнее

Aerie Continues Building On Rapid Growth Interview at Ophthalmology Innovation Summit @ ASCRS 2019Подробнее

Aerie Plans Next Step after RhopressaПодробнее

Aerie: Bringing Rhopressa and Roclatan into US glaucoma markeПодробнее

Aerie Pharmaceuticals - OIS@AAO 2015Подробнее